As part of the expansion, the company also has appointed new team members: Roy Ovel as chief commercial officer and Charles Denis Maher as vice president business development (Americas).
The expansion is primarily geographic and relates to “the ongoing growth of the Otimapharm business,” Oval told us.
“Many large pharmaceutical and biotechnology companies continue to find patient recruitment and retention a real challenge,” he added, commenting that the CRO has a reputation “for the recruitment of patients in a timely manner.” This, coupled with “reduced costs of performing studies in our core countries means we offer our clients complete peace of mind that we will recruit of patients for studies on time every time,” he said.
Optimapharm plans to further expand its footprint in “the coming months” through organically growth as well as by potential acquisitions.
Consolidating the CRO market
In January, Optimapharm acquired the Czech CRO MKS Research. Optimapharm CEO, Gordana Greguric Cicak, told us at the time that the company plans to double its revenue organically and through add-on acquisitions over the next three years.
“Our goal is to consolidate the CRO market in the CEE/SEE region [Central and Eastern Europe/South East Europe] and to become the largest independent in the whole of CEE/SEE,” Cicak said.
The company currently operates from 12 offices, including offices in 11 countries across Europe.